PolarityTE, Inc. (PTE) |
| 0.241 -0.002 (-0.82%) 06-15 16:00 |
| Open: | 0.2377 |
| High: | 0.2534 |
| Low: | 0.23 |
| Volume: | 8,317,499 |
| Market Cap: | 2(M) |
| PE Ratio: | -0.42 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 0.17 |
| Resistance 1: | 0.13 |
| Pivot price: | 0.08 |
| Support 1: | 0.06 |
| Support 2: | 0.05 |
| 52w High: | 1.9 |
| 52w Low: | 0.2 |
PolarityTE, Inc., a clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine Products and Contract Services. It offers SkinTE, a tissue product used to repair, reconstruction, replacement, and supplementation of skin in patients for the treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts, as well as contract research services. The company also develops SkinTE Cryo allows multiple deployments from one original harvest through a cryopreservation process; SkinTE point-of-care device to permit the processing and deployment of SkinTE immediately following the initial harvest at the point-of-car; PTE 11000, an allogenic, biologically active dressing for use in wound care and aesthetics to accelerate healing of skin; and other tissue regeneration products. PolarityTE, Inc. is headquartered in Salt Lake City, Utah.
| EPS | 0.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | 0.0 |
| Return on Equity (ttm) | 0.0 |
Thu, 06 Jul 2023
POLARITYTE, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K) - marketscreener.com
Thu, 06 Jul 2023
POLARITYTE, INC. : Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) - marketscreener.com
Tue, 27 Dec 2022
PolarityTE Announces Entry Into a Letter of Intent For Acquisition of the Company - PR Newswire
Fri, 13 May 2022
PolarityTE Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to SkinTE® - PR Newswire
Tue, 30 Mar 2021
Polarity TE Reports Narrower Net Loss For FY20 - RTTNews
Wed, 19 Jun 2019
What Type Of Shareholder Owns PolarityTE, Inc.'s (NASDAQ:PTE)? - Yahoo Finance
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |